In:
International Journal of Cancer, Wiley, Vol. 146, No. 4 ( 2020-02-15), p. 1086-1098
Abstract:
What's new? About one‐fifth of patients with high‐grade serous ovarian cancer (HGSOC) exhibit CCNE1 ‐amplification, which is associated with resistance to paclitaxel and other antimitotic agents used as frontline therapies against HGSOC. Here, to reinforce mitotic arrest and overcome spindle assembly checkpoint silencing, a major resistance mechanism in ovarian cancer, paclitaxel was combined with inhibition of both anaphase‐promoting complex/cyclosome (APC/C) and the pro‐survival protein MCL‐1. This combination successfully reduced cell proliferation and reactivated apoptosis in ovarian cancer cell lines and patient‐derived tumor cells. The findings warrant further investigation of paclitaxel and inhibition of APC/C and MCL‐1 as a therapeutic strategy in HGSOC.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Bookmarklink